Wells Fargo
RLMD icon

Wells Fargo’s Relmada Therapeutics RLMD Stock Holding History

Wells Fargo’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597K Buy
+86,263
New +$603K ﹤0.01% 4496
2025
Q1 		– Sell
-200
Closed -$104 – 7227
2024
Q4 		$104 Sell
200
-150
-43% -$366 ﹤0.01% 6410
2024
Q3 		$1.13K Hold
350
– – ﹤0.01% 6108
2024
Q2 		$1.05K Sell
350
-193
-36% -$698 ﹤0.01% 6084
2024
Q1 		$2.52K Buy
543
+3
+0.6% +$14 ﹤0.01% 5992
2023
Q4 		$2.24K Buy
540
+10
+2% +$30 ﹤0.01% 6088
2023
Q3 		$1.59K Sell
530
-4
-0.7% -$12 ﹤0.01% 6130
2023
Q2 		$1.31K Sell
534
-4,831
-90% -$13.4K ﹤0.01% 6273
2023
Q1 		$12.1K Buy
5,365
+4,222
+369% +$14.6K ﹤0.01% 5797
2022
Q4 		$3.99K Sell
1,143
-20,710
-95% -$182K ﹤0.01% 5829
2022
Q3 		$809K Sell
21,853
-3,179
-13% -$88.1K ﹤0.01% 3376
2022
Q2 		$476K Buy
25,032
+802
+3% +$17.5K ﹤0.01% 3776
2022
Q1 		$654K Buy
24,230
+15,841
+189% +$328K ﹤0.01% 4216
2021
Q4 		$189K Buy
8,389
+7,116
+559% +$158K ﹤0.01% 5297
2021
Q3 		$33K Sell
1,273
-8,272
-87% -$221K ﹤0.01% 5786
2021
Q2 		$306K Sell
9,545
-2,767
-22% -$96.1K ﹤0.01% 4858
2021
Q1 		$434K Sell
12,312
-30,822
-71% -$1.08M ﹤0.01% 4756
2020
Q4 		$1.38M Buy
43,134
+8,189
+23% +$281K ﹤0.01% 3774
2020
Q3 		$1.31M Sell
34,945
-4,013
-10% -$155K ﹤0.01% 3651
2020
Q2 		$1.74M Buy
38,958
+27,273
+233% +$1.15M ﹤0.01% 3363
2020
Q1 		$399K Buy
11,685
+1,526
+15% +$61.5K ﹤0.01% 4207
2019
Q4 		$396K Buy
+10,159
New +$309K ﹤0.01% 4548

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's RLMD Position: Q2 2026 in Review

Wells Fargo opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 86,263 shares worth $597K. The stake represents ﹤0.01% of the portfolio and ranks #4496 among its holdings. This is a return to the name: Wells Fargo previously reported a position in RLMD as recently as Q4 2024.

Wells Fargo first reported a position in RLMD in Q4 2019 and has held it in 22 quarters since. The position peaked at $1.74M in Q2 2020. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Wells Fargo held 86,263 shares of Relmada Therapeutics worth $597K as of Q2 2026.
  • Relmada Therapeutics was a new Wells Fargo position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4496 holding.
  • Wells Fargo first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Wells Fargo's Relmada Therapeutics position peaked at $1.74M in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.